Breast cancer survivors (BCSs) undergoing taxane-based chemotherapy frequently experience chemotherapy-induced peripheral neuropathy (CIPN), potentially affecting their quality of life.
Early identification of high-risk survivors can help mitigate the severity of CIPN.
